FUJIKURA
23.10.2020 10:02:07 CEST | Business Wire | Press release
Fujikura Ltd. (TOKYO:5803) (President & CEO: Masahiko Ito) today announced the introduction of industry’s most advanced and highly integrated Phased Array Antenna Module (PAAM) for 5G mmWave operating in 3GPP bands n257 (28 GHz), n258 (26 GHz) and n261 (27 GHz). The Fujikura PAAM is the industry’s highest performance PAAM targeting indoor and outdoor applications such as 5G mmWave Fixed Wireless Access (FWA), 5G mmWave Mobile Wireless Access (MWA), 5G mmWave wireless backhaul, and other emerging applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201023005099/en/
Key Differentiating Features of the Fujikura PAAM
The Fujikura PAAM is a high performance phased array antenna module with a novel integrated antenna, and supports concurrent dual polarized beams in both transmission and reception (Fig.1). The PAAM integrates best-in-class mmWave-ICs developed in-house using an industry leading SiGe BiCMOS process. The PAAM features extremely low noise figure (NF) characteristics and enables a large link margin for expanded coverage. Tunable true-time-delay-type phase shifters support precise and independent phase and amplitude control over a wide frequency range. The unique phase shifter not only enables simple beam-steering control which allows accurate beam steering with fine resolution, but also allows calibration-free operation making PAAM installation much easier. The phase shifter also maintains the transmitted or received signals undistorted by providing invariant group delay and unchanged beam direction in a wide frequency range. In addition, Fujikura PAAM provides superior digital reconfigurability allowing (1) flexible choices in the trade-off space between NF and linearity --- this enables a wide range of coverage applications simply through digital reconfiguration of the PAAM, and (2) on-chip support for 1000s of beam configurations. These are exactly the features highly desired by 5G wireless equipment manufacturers.
5G mmWave Market Growth
Currently, 5G deployments are accelerating around the world and mmWave bands are expected to play a significant role in enhancing the network capabilities. According to the Global mobile Suppliers Association (GSA), by the end of August, 2020, 397 operators in 129 countries and territories had announced investments in 5G. The deployment of 5G mmWave has started primarily in the US market for FWA and MWA, and we are now in the early stages. Markets are expecting substantial increase in 5G mmWave use cases including both outdoor and indoor deployments around the world. Fujikura will contribute to this market growth and benefit from it by providing 5G mmWave infrastructure customers with best-in-class PAAM products.
“Fujikura is announcing its first 5G mmWave RF-IC products for mobile infrastructure. Fujikura n257/n258/n261 PAAM products leverage field proven 5G mmWave IC1 and antenna in package2 technologies developed at IBM Research and enhanced by a Fujikura-led Joint Development Program3,4 . Leveraging our expertise in antenna design and substrate technologies as well as our long history and expertise in delivering differentiating products to the telecom industry, we are excited to introduce our new PAAM product family,” said Kenji Nishide, Fujikura R&D Managing Executive Officer. “Fujikura’s PAAM sets new benchmarks in terms of performance and low power consumption with the highest level of integration for 5G mmWave RF-ICs, which will contribute to growth and expansion of 5G mmWave networks and services.”
Product Introduction Schedule
Fujikura will provide samples for early access customers by the end of 1Q 2021 with volume production in 2H 2021.
For More Information
Please visit our website (https://mmwavetech.fujikura.jp/#area-28ghz-module
) and contact us.
About Fujikura
Fujikura Ltd. is a Tokyo-based company that has been providing wires and cables—“Tsunagu,” or connecting, technologies— to build social infrastructure since its foundation in 1885. With this expertise cultivated over 130 years, we commit to contribute to building social infrastructure by developing products for optical fibers, broadband wireless transmission, superconducting wires, electric vehicles, and other advanced technologies. Fujikura Group has approximately 57,000 employees in more than 30 countries, and posted sales revenue of US$6,178.7 million in Fiscal 2019. Find out more at www.fujikura.co.jp/eng
.
Reference
[1] https://www.ibm.com/blogs/research/2018/02/isscc-lewis-winner-award/
[2] https://www.ibm.com/blogs/research/2017/06/using-air-cavity-boost-performance-5g-antenna-module/
[3] https://www.fujikura.co.jp/eng/newsrelease/products/2058964_11777.html
[4] https://mmwavetech.fujikura.jp/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201023005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom